Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors (Cancer Gene Therapy (2008) 15, (795-807) DOI: 10.1038/cgt.2008.31);Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors

Cancer Gene Therapy

Volumn 15, Issue 12, 2008, Pages 795-807

  Yaacov, B ^a   Elihaoo, E ^a   Lazar, I ^b   Ben Shlomo, M ^a   Greenbaum, I ^a   Panet, A ^a   Zakay Rones, Z ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Apoptosis; Interferon; Lung cancer; NDV Newcastle disease virus; Oncolytic

Indexed keywords

BETA INTERFERON; INTERFERON;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG TUMOR; METASTASIS; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

AVES; MUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

EID: 56049097651     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.56     Document Type: Erratum

References (50)

1. Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol 2001; 12: 739-744.
2. Vora SA, Daly BD, Blaszkowsky L, McGrath JJ, Bankoff M, Supran S et al. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer 2000; 89: 1946-1952.
3. Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 2006; 80: 7522-7534.
4. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000; 16: 1-15.
5. Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z. The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol 1995; 121: 169-174.
6. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619-627.
7. Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 1999; 19: 635-638.
8. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221-228.
9. Schirrmacher V, Haas C, Bonifer R, Ertel C. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 1997; 3: 1135-1148.
10. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994; 54: 6017-6021.
11. Schirrmacher V, Ahlert T, Probstle T, Steiner HH, Herold-Mende C, Gerhards R et al. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25: 677-696.
12. Schirrmacher V, Jurianz K, Roth C, Griesbach A, Bonifer R, Zawatzky R. Tumor stimulator cell modification by infection with Newcastle disease virus: analysis of effects and mechanism in MLTC-CML cultures. Int J Oncol 1999; 14: 205-215.
13. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 1988; 80: 1305-1312.
14. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 1994; 9: 225-235.
15. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80: 5145-5155.
16. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
17. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275.
18. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627-639.
19. Weaver BK, Ando O, Kumar KP, Reich NC. Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53. FASEB J 2001; 15: 501-515.
20. Bar-Eli N, Giloh H, Schlesinger M, Zakay-Rones Z. Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol 1996; 122: 409-415.
21. Cheville NF, Beard CW. Cytopathology of Newcastle disease. The influence of bursal and thymic lymphoid systems in the chicken. Lab Invest 1972; 27: 129-143.
22. Hitchner SB, Johnson EP. A virus of low virulence for immunizing fowls against Newcastle disease (avian pneumoencephalitis). Vet Med 1948; 43: 525-530.
23. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O et al. Combined treatment of pediatric highgrade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 2006; 114: 731-743.
24. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 973; 51: 1417-1423.
25. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature 1970; 227: 168-170.
26. Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E et al. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res 2005; 11: 4955-4961.
27. Sever JL. Application of a microtechnique to viral serological investigations. J Immunol 1962; 88: 320-329.
28. Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ et al. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol 2005; 71: 223-229.
29. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004; 18: 1240-1242.
30. Pitha PM, Kunzi MS. Type I interferon: the ever unfolding story. Curr Top Microbiol Immunol 2007; 316: 41-70.
31. Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol 2001; 38: 179-193.
32. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34: 1514-1521.
33. Matza-Porges S, Horresh I, Tavor E, Panet A, Honigman A. Expression of an anti apoptotic recombinant short peptide in mammalian cells. Apoptosis 2005; 10: 987-996.
34. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 1999; 9: 83-99.
35. Castagnetta LA, Carruba G. Human prostate cancer: a direct role for oestrogens. Ciba Found Symp 1995; 191: 269-286.
36. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999; 73: 5001-5009.
37. Romer-Oberdorfer A, Werner O, Veits J, Mebatsion T, Mettenleiter TC. Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity. J Gen Virol 2003; 84(Partt 11): 3121-3129.
38. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 2006; 119: 328-338.
39. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77: 9522-9532.
40. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N et al. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 2003; 77: 1501-1511.
41. Apostolidis L, Schirrmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 2007; 31: 1009-1019.
42. Fabian Z, Csatary CM, Szeberenyi J, Csatary LK. p53-Independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 2007; 81: 2817-2830.
43. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-2266.
44. Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 2007; 13: 977-985.
45. Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992; 267: 13573-13579.
46. Stram Y, Shchori D, Chinitch Y, David D, Molad T, Samina I. Molecular characterization of an unassigned Israeli Newcastle disease virus isolate. Avian Dis 1998; 42: 746-751.
47. Reed LJ, Muench HA. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497.
48. Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ 1973; 48: 199-202.
49. Luther P, Klett GE, Weber S, Pechmann H, Bergmann KC. The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. J Biol Stand 1983; 11: 115-121.
50. Gotoh BYF, Ogasawara T, Nagai Y. Isolation of factor Xa from chick embryo as the amniotic endoprotease responsible for paramyxovirus activation. FEBS Lett 1992; 296: 274-278.